Systematic review of randomized controlled trials on antibiotic treatment for osteomyelitis in diabetes. Issue 5 (13th March 2019)

• Record Type: Journal Article
• Authors: Xing, K.; Huang, G.; Hua, S.; Xu, G.; Li, M.
• Is Part Of: Diabetic medicine. Volume 36:Issue 5(2019)
• Page Start: 546
• Page End: 556
• Publication Date: 2019-03-13
• Subjects: Diabetes -- Periodicals; 616.462
• DOI: 10.1111/dme.13935
• Languages: English
• ISSNs: 0742-3071

Abstract

Abstract: Aim: To evaluate the efficacy of antibiotic therapy in osteomyelitis treatment among people with diabetes. Methods: A systematic search of PubMed, EMBASE, AMED, Web of Science, the WHO trial registry, Cochrane library databases, and ClinicalTrials.gov, in addition to hand‐searching, was undertaken in July 2018. Two reviewers independently extracted data. The studies' methodological quality was assessed using the modified Jadad scale. Descriptive analysis was performed. Results: Seven randomized controlled trials, with 393 participants in total, were included. The antibiotic regimens, treatments and follow‐up durations varied among the trials. The total scores showed that the overall methodological quality of the seven studies was high, despite two studies showing some flaws in double‐blinding and withdrawals/drop‐outs. Of four studies comparing different antibiotic regimens, three implied a similar remission effect, while one implied that ertapenem ± vancomycin treatment showed a higher remission rate than tigecycline treatment; this conclusion was not robust because of low power and small sample size. In the other three studies, which included two different doses of ciprofloxacin, an antibiotics group and a conservative surgical group, and two durations of the same antibiotic strategy, no significant differences in remission were reported between the groups. No difference was observed in the analyses of microbiological outcomes, superinfections and relapse, except adverse events. Conclusions: There is no definitive evidence supporting the superiority of any particular antibiotic agent, dose, or administration duration in the treatment of osteomyelitis in diabetes. As the included studies had some flaws and limitations, further research is necessary. What's new?: Osteomyelitis is perhaps the most difficult‐to‐treat complication of diabetes. In this review we evaluated the efficacy of antibiotic therapy in osteomyelitis treatment among people with diabetes. No definite evidence was found supporting the superiority of any particular antibiotic agent, dose, or administration duration in the treatment of osteomyelitis in diabetes. Improving on the flaws observed in previous studies could prove beneficial in optimizing the design of future studies on diabetes‐related osteomyelitis.